Dipeptidyl Peptidase-4 Inhibitors

Dipeptidyl peptidase-4 (DPP-4) inhibitors are indicated for treatment of type II diabetes and work by inhibiting DPP-4, which acts as an inactivator of incretins. Incretins, such as GLP-1, enhance insulin secretion and decrease hepatic secretion of glucagon.   Pancreatitis is a known adverse effect.

Class Drugs

• Alogliptin

• Linagliptin

• Saxagliptin

• Sitagliptin

Class Mechanism of Action

Inhibits DPP-4 (dipeptidyl peptidase-4)

• DPP-4 inactivates incretin hormones, so inhibition of DPP-4 extends activity of incretins resulting in increased insulin release and decreased secretion of glucagon

Class Applications

Type II Diabetes Mellitus

Class Adverse Effects

Pancreatitis

Nasopharyngitis

Drug Table

Drug Name	Application	Comments	Image
Alogliptin			"Alo Yoga" "Lipton tea"
Linagliptin			"Line" "Lipton tea"
Saxagliptin			"Saxophone" "Lipton Tea"
Sitagliptin			"Sit" "Lipton Tea"